Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 7/20 | 0.50 |
| ▸ | GABRD | O14764 | 7/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 7/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.50 |
| ▸ | GABRE | P78334 | 7/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 7/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 7/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 7/20 | 0.50 |
| ▸ | DAO | P14920 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162217 | 0.87 | MEN1 (0.55) | DAOMEN1LMNAKMT2AL3MBTL1 | |
| SCHEMBL20162226 | 0.85 | AURKA (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18386905 | 0.85 | DAO (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18386767 | 0.81 | CDK5 (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30615643 | 0.78 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18386902 | 0.74 | CDC7 (0.38) | MEN1KMT2ATRPV1TGFBR1 | |
| SCHEMBL16657379 | 0.72 | DAO (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18585985 | 0.72 | MAPK14 (0.36) | TRPV1 | |
| SCHEMBL16657378 | 0.71 | GABRP (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28836828 | 0.71 | MAPK14 (0.37) | MEN1KMT2ATRPV1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323817-B1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-10-19 | — | — | EP | disclosed |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| EP-3323817-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-05-23 | — | — | EP | disclosed |
| EP-3323817-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-05-23 | — | — | EP | disclosed |
| WO-2017008761-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | 正大天晴药业集团股份有限公司 | 2017-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | EGFR, ERBB2, ERBB3 | GABRP 2240/4885GABRD 3113/4885GABRA1 2867/4885 |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | EGFR, ERBB2, ERBB3 | GABRP 616/4885GABRD 1334/4885GABRA1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.